Purpose The purpose of this study was to evaluate possible risk factors for falls in a group of patients with chemotherapy-induced peripheral neuropathy (CIPN). Methods This prospective, descriptive study included persons receiving paclitaxel, docetaxel, oxaliplatin, or cispatin who reported at least one symptom of CIPN. Each patient was invited to complete the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) and a demographic data questionnaire. Data were analyzed using descriptive statistics and logistic regression. Results In this sample (n=109), fallers (n=21) had higher doses of chemotherapy(p=0.045), more neuropathic symptoms (p=0.016), higher scores on the symptom experience (p=0.005) and interference items (=0.001) on the CIPNAT, more severe muscle weakness (p<0.001) and loss of balance (p<0.001), and higher interference with walking (p<0.001) and driving (p=0.022). Patients who received taxanes were more likely to have fallen than patients who received platinum-based chemotherapy (p=0.022). No significant differences in age or disease stage between fallers and non-fallers were present. Severity of loss of balance and cycle number was independently associated with falling. Conclusions This study demonstrates that the risk of falls increases with each cycle of chemotherapy and that patients receiving taxanes may be at greater risk of falls than patients receiving neurotoxic platinum-based drugs.
etiology [10] [11] [12] [13] . Diminished sensation and loss of neuromuscular control of the lower extremities may escalate to eventually interfere with balance and gait. Previous research has demonstrated that peripheral neuropathy is an under-recognized risk factor for falls [12] . Risk factors for falls in persons with CIPN have not been previously studied. The purpose of this study was to evaluate possible risk factors for falls in a group of patients with CIPN. The following research questions guided this study:
(1) What differences in demographic and disease-related characteristics, neuropathic symptoms, and functional performance exist between fallers and non-fallers with CIPN? (2) What are the most significant risk factors for falls in persons with CIPN?
Review of literature
Risk factors for falls in persons receiving chemotherapy
Advancing age, fatigue, generalized weakness, muscle weakness and atrophy, anemia, and poor performance status increase the concern for falls in persons receiving chemotherapy [14, 15] . Older adults aged 75 years and older are up to five times more likely to fall as compared to people aged 65 years or less [16] . Generalized weakness for people who are diagnosed with cancer can be influenced by factors such as anemia, fatigue, and muscle weakness. Anemia is a common complication associated with cancer and cancer treatment. Patients with anemia have less red blood cells and therefore less oxygen carrying capability resulting in tiredness or fatigue. Fatigue is related to fall risk and can be a prime factor in motivating falls [17] . Fatigue can lead to a general weakness and functional status problems, which are also motivations for a fall [18] .
Functional status
Functional status is the ability to perform activities that are integral to independence [19] . An older adult who is diagnosed with cancer and is impaired in functional status has a greater risk of falls [2] . Persons who have difficulty performing activities such as bathing, dressing, or transferring are more likely to fall and are more likely to be hospitalized [20] and are also more likely to become frail [21] . Functional status, and not age, is a reasonable indicator of cancer treatment tolerance [22] . Functional status is a valuable assessment measure that can help understand a more complete picture of health status as compared to a traditional patient assessment. Performance status is a clinical evaluation intended to provide an insight into understand how a person walks, balance, and other things, such as grip strength. Performance status measures are often objective measurements such as the Timed Up & Go (TUG) Instrument [23] and grip-strength measures [24] . People with poor grip are not only at risks for falls, but have an increased risk for mortality [24] . People diagnosed with cancer and undergoing cancer treatment may have occasions when performance status measures may not be as robust compared to a time when the patient was not undergoing cancer therapy. Occasions when patients are experiencing weakness resulting in problems with balance, gait, or strength are prime opportunities for falls. As part of the oncology assessment, functional status concerns must be addressed in order to better predict falls, and perhaps reduce the changes of serious injury in older adults receiving cancer treatment.
Risk factors for falls in persons with peripheral neuropathy
Much of what is known about peripheral neuropathy and falls comes from the literature on diabetes, and the research has primarily been conducted by researchers in physical therapy and rehabilitative medicine. Conservative gait pattern with decreased walking speed and smaller step size are compensatory mechanisms that have been documented in individuals with peripheral neuropathy [25, 26] . A previous study by Macgilchrist and colleagues (2010) sought to identify risk factors for falls in diabetics with peripheral neuropathy and identified decreased walking velocity, decreases strength of ankle dorsiflexors, and severity of peripheral neuropathy as significant fall predictors [27] . Reduced leading toe-obstacle clearances, leading to an increased risk of tripping over obstacles, have also been observed in diabetics at risk for or having peripheral neuropathy [28] . Several studies have shown that physical activity including gait, balance, and resistance training may be useful in improving balance and reducing in people with peripheral neuropathy [10, [29] [30] [31] [32] .
While this information has many implications for future research, few studies have included oncology patients and little is known about assessment, or management of fall risk in individuals with CIPN. Clinical trials of neurotoxic chemotherapy drugs have evaluated the frequency and severity of neuropathy as a side effect but stopped short of evaluating the effects of neuropathy on patient safety or fall risk [33] [34] [35] . While several studies have examined the negative impact of CIPN on physical performance, specific risk factors for falls in persons receiving neurotoxic chemotherapy have not been adequately addressed in the literature [28, [36] [37] [38] [39] . This study is one of the first to evaluate risk factors for falls in persons with CIPN.
Methods

Design, sample, and setting
This prospective, descriptive study included persons receiving paclitaxel, docetaxel, oxaliplatin, or cispatin for treatment of any cancer. The sample was accrued at two sites; a large National Cancer Institute, designated Comprehensive Cancer Center in west central Florida, and a private medical oncology practice in the same geographic area. To be included in this study, patients should (1) be able to speak and understand English; (2) should be between 18 and 90 years of age; and (3) report at least one neuropathic symptom on the Chemotherapy Induced Peripheral Neuropathy Assessment Tool (CIPNAT).
Instruments
Demographic data form A demographic data form was developed for this study and included age, gender, race/ethnicity, education, marital status, income, years of formal education, employment status, type of cancer, type of chemotherapy, number of cycles of chemotherapy, and cumulative dose of neurotoxic agent. Information about chemotherapy drugs and doses was obtained by the researcher from the medical record.
Chemotherapy-induced peripheral neuropathy assessment tool
Neuropathic symptoms, functional status, and incidence of falls were measured using the CIPNAT [40] . The CIPNAT is a 50-item instrument that contains two sets of items: symptom experience items and interference items. The 36 symptom experience items measure severity, distress, and frequency of nine neuropathic symptoms including; numbness in the hands, numbness in the feet, tingling in the hands, tingling in the feet, sensitivity to cold temperatures, nerve pain, muscle/joint aches, muscle weakness, and loss of balance. Participants are first asked whether they have developed any of the nine symptoms since receiving chemotherapy. For each symptom reported, participants are asked to rate the intensity, distress, and frequency of that symptom on a 0-10 numeric rating scale. The symptom experience item set is scored by adding the number of symptoms reported (0-9) with the severity, distress, and frequency scores for each reported symptom. Scores range from 0 to 279 with higher scores corresponding with higher levels of CIPN.
The 14 interference items assess neuropathic interference with usual activities (functional status). These items ask participants to rate how much their symptoms interfere with Two descriptive items were added to the CIPNAT to assess whether participants had sustained any injuries as a result of neuropathic symptoms. If they answered positively, they were then asked for a description of the injury. Patients who reported falls were classified as fallers, and those who reported no injury or non-fall-related injuries were classified as non-fallers.
Procedures
The study was approved by the Protocol Research Monitoring Committee at the Cancer Center and the IRB of the University of South Florida. Patients were invited to participate during a regularly scheduled visit to the infusion center. The study was explained, questions answered, and the consent signed before data collection began. Patients completed the CIPNAT and demographic data form. Information on type of cancer, type of chemotherapy, number of cycles of chemotherapy, and cumulative dose of neurotoxic agent were obtained from the medical record.
Data analysis
For the purpose of analyzing differences in falls between classes of chemotherapy, participants receiving taxanes (paclitaxel and docetaxel) were grouped together and participants receiving platinum-based chemotherapies (cisplatin and oxaliplatin) were grouped together. To analyze differences in falls between stages of disease, cancer stages I and II were grouped together as early stage and cancer stages III, IV or extensive were grouped together as late stage.
All data were analyzed using the Software Package for the Social Sciences version 17. Demographic data are presented as frequencies and means and standard deviations. In univariate analyses, mean values of demographic, treatment, and neuropathic symptom variables were compared between fallers (n=21) and non-fallers (n=88) by use of student t tests and Mann-Whitney U tests. Similarly, chi- square tests were used to compare percentages of drug class and disease stage between fallers and non-fallers. Variables identified as statistically significant in univariate analyses were used in a forward stepwise logistic regression model to identify factors independently associated with falling. A p value of <0.05 was used to define statistical significance for all analyses.
Results
Sample
The sample consisted of predominantly Caucasian participants with solid tumors in stage III or IV ( Table 1 ). The majority were married (66.1%) and female (63.3%).
Participants represented a diverse range of incomes. The mean age was 58.4 (SD=11.8) and participants reported a mean of 14.1 years (SD=2.6 years) of formal education. They had received a mean of 5.6 cycles (SD=5.1 cycles) of chemotherapy with mean cumulative doses of 544.4(SD= 722.7) of neurotoxic chemotherapy drug.
Differences between fallers and non-fallers
In this sample, 19.3% (n=21) of participants reported at least one fall since beginning chemotherapy. Fallers had received higher cumulative doses of chemotherapy, had a significantly higher number of neuropathic symptoms (p= 0.016), higher total scores on the entire CIPNAT(p=0.001), as well as both the symptom experience (p=0.005) and interference items of the CIPNAT (p=0.001), more severe muscle weakness (p<0.001) and loss of balance (p<0.001), and higher interference with walking (p<0.001) and driving (p=0.022) ( Table 2) . Participants who received a taxane (paclitaxel or docetaxel) were more likely to have fallen (p=0.022) than those who had received a platinum-based chemotherapy drug (cisplatin or oxaliplatin) ( Table 3) . No significant differences between fallers and non-fallers in age, gender, stage of disease, or other demographic characteristics were detected.
Fall predictors
In logistic regression analyses, loss of balance (odds ratio= 1.45, p=0.005) and cycle number (odds ratio=1.33, p=0.04) were independently associated with falling, whereas interference with walking (odds ratio=1.28, p=0.06) and taxane drug class (odds ratio=10.14, p=0.07) were borderline significant ( Table 4 ). The confidence interval for the estimated effect of taxane drug class (0.84-122.1) was very wide due to only three fallers in the platinum drug class group.
Discussion
This study identifies potential risk factors for falls in persons with CIPN including cumulative dose and cycle number, severity of loss of balance, severity of muscle weakness, self-reported interference with walking or driving, number of neuropathic symptoms, severity of CIPN, and performance status. Patients receiving taxanes may be at higher risk for falls during chemotherapy than patients receiving platinum-based chemotherapy drugs. Significant differences in muscle weakness and loss of balance existed between fallers and non-fallers. Patient reported loss of balance was a significant predictor of falls in this study. Muscle weakness and loss of balance are [41] [42] [43] . This study suggests that the risk of falls increases with cumulative doses and chemotherapy cycles and that persons with higher peripheral neuropathy scores are at higher risk of falls. Fallers scored significantly higher on the CIPNAT, including number of symptoms, symptom experience items, and interference items than did non-fallers. Assessment of CIPN using a reliable and valid self-report tool may be helpful in identifying patients at risk for falls.
The majority of patients in this study had advanced stages of cancer, which may have contributed to the insignificant difference in disease stage between fallers and non-fallers. Future studies should include larger sample sizes and include more patients with early stage disease. The lack of significant differences in age between fallers and non-fallers suggest that older individuals may tolerate neurotoxic chemotherapy as well as younger ones. This supports the findings of previous research demonstrating that older adults have a similar risk of developing CIPN than their younger counterparts and among those that do develop neuropathy, the severity levels are similar between older and younger patients [44] .
Finally, this study suggests that patients receiving taxanes may be at a higher risk of falling during chemotherapy than patients receiving platinum-based drugs. CIPN symptoms may vary based upon which neurotoxic chemotherapy drug(s) are given [45] . The sample size did not allow for comparison by neurotoxic drug alone. Future research should include comparisons between individual drugs, especially because neuropathic symptoms vary according to both drug class and individual drug being used.
